Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
Add more filters










Publication year range
1.
J Steroid Biochem Mol Biol ; 216: 106039, 2022 02.
Article in English | MEDLINE | ID: mdl-34861389

ABSTRACT

We evaluated oxyphytosterol (OPS) concentrations in plasma and various tissues of two genetically modified mouse models with either increased cholesterol (apoE KO mice) or increased cholesterol and plant sterol (PS) concentrations (apoExABCG8 dKO mice). Sixteen female apoE KO and 16 dKO mice followed the same standard, low OPS-chow diet. Animals were euthanized at 36 weeks to measure PS and OPS concentrations in plasma, brain, liver and aortic tissue. Cholesterol and oxysterol (OS) concentrations were analyzed as reference for sterol oxidation in general. Plasma campesterol (24.1 ± 4.3 vs. 11.8 ± 3.0 mg/dL) and sitosterol (67.4 ± 12.7 vs. 4.9 ± 1.1 mg/dL) concentrations were severely elevated in the dKO compared to the apoE KO mice (p < 0.001). Also, in aortic and brain tissue, PS levels were significantly elevated in dKO. However, plasma, aortic and brain OPS concentrations were comparable or even lower in the dKO mice. In contrast, in liver tissue, both PS and OPS concentrations were severely elevated in the dKO compared to apoE KO mice (sum OPS: 7.4 ± 1.6 vs. 4.1 ± 0.8 ng/mg, p < 0.001). OS concentrations followed cholesterol concentrations in plasma and all tissues suggesting ubiquitous oxidation. Despite severely elevated PS concentrations, OPS concentrations were only elevated in liver tissue, suggesting that OPS are primarily formed in the liver and plasma concentrations originate from hepatic spill-over into the circulation.


Subject(s)
Liver/metabolism , Oxysterols/blood , Phytosterols/blood , ATP Binding Cassette Transporter, Subfamily G, Member 8/genetics , Animals , Apolipoproteins E/genetics , Cholesterol/analogs & derivatives , Cholesterol/blood , Cholesterol/metabolism , Female , Lipid Metabolism/genetics , Lipoproteins/genetics , Mice , Mice, Knockout , Oxidation-Reduction , Oxysterols/metabolism , Phytosterols/metabolism , Sitosterols/blood , Sitosterols/metabolism
2.
Lipids Health Dis ; 20(1): 112, 2021 Sep 21.
Article in English | MEDLINE | ID: mdl-34548089

ABSTRACT

BACKGROUND: Increased physical activity is inversely related to the risk to develop cardiovascular disease (CVD). In a recent systematic review, it was reported that CVD patients had an increased cholesterol absorption and a decreased synthesis as compared with control participants. As increased physical activity levels reduce CVD risk, we hypothesized that exercise training will reduce cholesterol absorption and increase endogenous cholesterol synthesis in older overweight and obese men. METHODS: A randomized, controlled, crossover trial was performed. Seventeen apparently healthy older overweight and obese men were randomized to start with an aerobic exercise or no-exercise control period for 8 weeks, separated by 12 weeks washout. Fasting serum total cholesterol (TC) and non-cholesterol sterol concentrations were measured at baseline, and after 4 and 8 weeks. RESULTS: The aerobic exercise program did not affect serum TC concentrations. In addition, exercise did not affect TC-standardized serum concentrations of sitosterol and cholestanol that are markers for cholesterol absorption. However, a trend for reduced TC-standardized campesterol concentrations, which is another validated marker for cholesterol absorption, was observed as compared with control. Lathosterol concentrations, reflecting cholesterol synthesis, did not differ between both periods. CONCLUSIONS: Aerobic exercise training for 8 weeks did not lower serum TC concentrations in older overweight and obese men, but a trend towards a decrease in the cholesterol absorption marker campesterol was found. The cholesterol synthesis marker lathosterol did not change. TRIAL REGISTRATION: posted on www.clinicaltrials.gov as NCT03272061 on 7 September 2017.


Subject(s)
Cardiovascular Diseases/blood , Cardiovascular Diseases/prevention & control , Cholesterol/blood , Exercise Therapy/methods , Exercise , Obesity/therapy , Overweight/therapy , Aged , Biomarkers/blood , Body Mass Index , Cholesterol/analogs & derivatives , Cholesterol/chemistry , Cross-Over Studies , Humans , Life Style , Male , Middle Aged , Phytosterols/blood , Sterols/blood , Surveys and Questionnaires
3.
Prog Lipid Res ; 74: 87-102, 2019 04.
Article in English | MEDLINE | ID: mdl-30822462

ABSTRACT

Dietary plant sterols and stanols as present in our diet and in functional foods are well-known for their inhibitory effects on intestinal cholesterol absorption, which translates into lower low-density lipoprotein cholesterol concentrations. However, emerging evidence suggests that plant sterols and stanols have numerous additional health effects, which are largely unnoticed in the current scientific literature. Therefore, in this review we pose the intriguing question "What would have occurred if plant sterols and stanols had been discovered and embraced by disciplines such as immunology, hepatology, pulmonology or gastroenterology before being positioned as cholesterol-lowering molecules?" What would then have been the main benefits and fields of application of plant sterols and stanols today? We here discuss potential effects ranging from its presence and function intrauterine and in breast milk towards a potential role in the development of non-alcoholic steatohepatitis (NASH), cardiovascular disease (CVD), inflammatory bowel diseases (IBD) and allergic asthma. Interestingly, effects clearly depend on the route of entrance as observed in intestinal-failure associated liver disease (IFALD) during parenteral nutrition regimens. It is only until recently that effects beyond lowering of cholesterol concentrations are being explored systematically. Thus, there is a clear need to understand the full health effects of plant sterols and stanols.


Subject(s)
Asthma/drug therapy , Cardiovascular Diseases/drug therapy , Inflammatory Bowel Diseases/drug therapy , Non-alcoholic Fatty Liver Disease/drug therapy , Phytosterols/pharmacology , Sitosterols/pharmacology , Asthma/metabolism , Cardiovascular Diseases/metabolism , Cholesterol/metabolism , Cholesterol, LDL/antagonists & inhibitors , Cholesterol, LDL/metabolism , Humans , Inflammatory Bowel Diseases/metabolism , Intestinal Absorption/drug effects , Non-alcoholic Fatty Liver Disease/metabolism , Phytosterols/administration & dosage , Sitosterols/administration & dosage
4.
Chem Phys Lipids ; 207(Pt B): 239-245, 2017 10.
Article in English | MEDLINE | ID: mdl-28647339

ABSTRACT

BACKGROUND: Changes in the microbiota composition have been implicated in the development of obesity and type 2 diabetes. However, not much is known on the involvement of gut microbiota in lipid and cholesterol metabolism. In addition, the gut microbiota might also be a potential source of plasma oxyphytosterol and oxycholesterol concentrations (oxidation products of plant sterols and cholesterol). Therefore, the aim of this study was to modulate the gut microbiota by antibiotic therapy to investigate effects on parameters reflecting cholesterol metabolism and oxyphytosterol concentrations. DESIGN: A randomized, double blind, placebo-controlled trial was performed in which 55 obese, pre-diabetic men received oral amoxicillin (broad-spectrum antibiotic), vancomycin (antibiotic directed against Gram-positive bacteria) or placebo (microcrystalline cellulose) capsules for 7days (1500mg/day). Plasma lipid and lipoprotein, non-cholesterol sterol, bile acid and oxy(phyto)sterol concentrations were determined at baseline and after 1-week intervention. RESULTS: Plasma secondary bile acids correlated negatively with cholestanol (marker for cholesterol absorption, r=-0.367; P<0.05) and positively with lathosterol concentrations (marker for cholesterol synthesis, r=0.430; P<0.05). Fasting plasma secondary bile acid concentrations were reduced after vancomycin treatment as compared to placebo treatment (-0.24±0.22µmol/L vs. -0.08±0.29µmol/L; P<0.01). Vancomycin and amoxicillin treatment did not affect markers for cholesterol metabolism, plasma TAG, total cholesterol, LDL-C or HDL-C concentrations as compared to placebo. In addition, both antibiotic treatments did not affect individual isoforms or total plasma oxyphytosterol or oxycholesterol concentrations. CONCLUSION: Despite strong correlations between plasma bile acid concentrations and cholesterol metabolism (synthesis and absorption), amoxicillin and vancomycin treatment for 7days did not affect plasma lipid and lipoprotein, plasma non-cholesterol sterol and oxy(phyto)sterol concentrations in obese, pre-diabetic men.


Subject(s)
Amoxicillin/pharmacology , Anti-Bacterial Agents/pharmacology , Cholesterol/metabolism , Vancomycin/pharmacology , Administration, Oral , Amoxicillin/administration & dosage , Anti-Bacterial Agents/administration & dosage , Bile Acids and Salts/blood , Bile Acids and Salts/metabolism , Cholesterol/blood , Double-Blind Method , Humans , Male , Middle Aged , Obesity/blood , Obesity/metabolism , Prediabetic State/blood , Prediabetic State/metabolism , Vancomycin/administration & dosage
5.
J Clin Endocrinol Metab ; 100(9): 3572-80, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26186296

ABSTRACT

CONTEXT: Despite stabilization of childhood overweight and obesity prevalence, there is a shift toward more severe degrees of obesity, which results in an increasing prevalence of children with morbid obesity. Prior studies demonstrated that lifestyle modification without ongoing treatment has only a modest and not sustainable effect in children with morbid obesity. This suggests that a chronic care model is necessary for long-term effects on weight management and health. OBJECTIVE: This study aimed to evaluate the effect of an ongoing lifestyle intervention in children with morbid obesity in comparison with children with overweight and obesity. DESIGN AND SETTING: This was a nonrandomized prospective intervention study with 12- and 24-month followup at the Centre for Overweight Adolescent and Children's Healthcare. PATIENTS AND INTERVENTION: Children and adolescents (n = 100 females and 72 males) with overweight, obesity, or morbid obesity were given long-term, outpatient, tailored lifestyle intervention. MAIN OUTCOME MEASURE: Body mass index (BMI) z score was measured. RESULTS: In children with morbid obesity, 12- and 24-month interventions resulted in a decrease of BMI z score of -0.13 ± 0.25 (P = .001) and -0.23 ± 0.32 (P = .01) respectively, whereas weight status category improved to obese in 21% and 25% of the children. Cardiovascular risk parameters including serum total cholesterol, low-density lipoprotein cholesterol, glycosylated hemoglobin (HbA1c), and diastolic blood pressure significantly improved after 1-year intervention in the complete group. Most important, BMI z score as well as cardiovascular risk parameters improved to a similar degree in children with overweight, obesity, and morbid obesity. CONCLUSIONS: Children with overweight, obesity, and morbid obesity benefit equally from an ongoing, outpatient, tailored lifestyle intervention, and demonstrate significant weight loss and improvement of cardiovascular risk parameters.


Subject(s)
Behavior Therapy , Life Style , Obesity, Morbid/therapy , Overweight/therapy , Adolescent , Body Mass Index , Child , Female , Humans , Male , Obesity, Morbid/psychology , Overweight/psychology , Prospective Studies , Treatment Outcome , Weight Loss
6.
Ned Tijdschr Tandheelkd ; 122(3): 139-40, 2015 Mar.
Article in Dutch | MEDLINE | ID: mdl-26181390

ABSTRACT

In the December issue of the Nederlands Tijdschrift voor Tandheelkunde (Dutch Journal of Dentistry) in 2014, an article was devoted to the use of light sedation with midazolam by dentists. A number of dentists who are active in the area of Special Dentistry (anxiety management, care of the disabled) and a anesthesiologist offer a response to the article and argue that the administration of intravenous sedation with midazolam by dentists is unsafe.


Subject(s)
Anesthetics, Intravenous/adverse effects , Dental Anxiety/drug therapy , Midazolam/adverse effects , Patient Safety , Anesthesia, Intravenous , Anesthetics, Intravenous/administration & dosage , Conscious Sedation , Humans , Midazolam/administration & dosage , Treatment Outcome
7.
Nutr Metab Cardiovasc Dis ; 25(2): 210-7, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25456153

ABSTRACT

BACKGROUND AND AIMS: Earlier studies in our group suggested that traditionally prepared buttermilk influences cholesterol metabolism. We therefore designed a study to evaluate whether traditionally prepared buttermilk lowers serum low-density lipoprotein cholesterol (LDL-C) and/or prevents the LDL-C raising effect of egg yolks. METHODS AND RESULTS: Mildly hypercholesterolemic subjects were randomly allocated to one of four diet groups consuming daily at lunch 80 ml skimmed milk with (n = 23) or without (n = 25) lutein-enriched egg yolk (28 g from 1.5 eggs providing 323 mg cholesterol) or traditionally prepared buttermilk with (n = 23) or without (n = 21) lutein-enriched egg yolk during a 12 week period. Fasting blood samples were taken to measure concentrations of serum lipids, (apo)lipoproteins, liver and kidney function markers, and plasma lutein, zeaxanthin and high-sensitive C-reactive protein (hsCRP). Egg yolk consumption significantly increased serum total cholesterol (total-C) (p = 0.035) and LDL-C concentrations (p = 0.022). Buttermilk did not change the effects of egg yolk on serum lipids and (apo)lipoproteins. There was a trend towards significant lower total-C (p = 0.077), but not LDL-C (p = 0.204) concentrations in the buttermilk groups. Plasma lutein and zeaxanthin concentrations increased significantly (p < 0.001) in the egg yolk groups. CONCLUSION: In mildly hypercholesterolemic subjects, daily consumption of traditionally prepared buttermilk for 12 weeks did not lower serum total-C or LDL-C concentrations, nor did it prevent the serum total-C and LDL-C raising effect of daily egg yolk consumption. REGISTRATION NUMBER: This study is registered at www.clinicaltrials.gov as NCT01566305.


Subject(s)
Cultured Milk Products/chemistry , Egg Yolk/chemistry , Hypercholesterolemia/blood , Lutein/administration & dosage , Aged , Animals , Biomarkers/blood , Body Mass Index , C-Reactive Protein/metabolism , Cholesterol/blood , Cholesterol, LDL/blood , Dietary Carbohydrates/administration & dosage , Dietary Fats/administration & dosage , Fasting , Fatty Acids/administration & dosage , Female , Healthy Volunteers , Humans , Lutein/blood , Male , Middle Aged , Zeaxanthins/blood
8.
Eur J Clin Nutr ; 69(1): 127-33, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25271015

ABSTRACT

BACKGROUND/OBJECTIVES: Plant stanol esters lower serum low-density lipoprotein (LDL)-cholesterol (LDL-C), but responses between individuals vary widely. As the ability of subjects to respond to acute dietary challenges may reflect the flexibility to adapt to changes on the longer term, we related subjects' acute postprandial metabolic changes to changes in serum lipoproteins after chronic intake of plant stanol esters. SUBJECTS/METHODS: In a double-blind crossover design, 20 healthy subjects received in random order a high-fat shake enriched with or without plant stanol esters (4 g). Blood samples were taken during 4 h to examine lipid, glucose and lipoprotein profiles. Two subjects dropped out. For the 3 weeks after this postprandial test, the subjects who received the shake with plant stanol esters continued the consumption of plant stanol-enriched (3g/day) margarine and subjects receiving the control shake in the postprandial test consumed for the next 3 weeks a control margarine. After the washout period, subjects received the other shake and margarines. RESULTS: The margarine enriched with plant stanol esters lowered concentrations of total cholesterol by 7.3% (P<0.01), LDL-C by 9.5% (P<0.01) and apoB100 by 8.6% (P<0.01). Furthermore, particle concentrations of total very low-density lipoprotein (VLDL), small VLDL and large LDL were reduced by 26.6% (P=0.02), 27.6% (P=0.02) and 12.3% (P=0.04), respectively. Plant stanol esters did not affect parameters related to lipid and glucose metabolism during the postprandial phase. However, the incremental area under the curve (iAUC) of the postprandial glucose concentration after consuming the control shake correlated positively with changes in fasting concentrations of total cholesterol, LDL-C, apoB100, total VLDL, small VLDL and intermediate-density lipoprotein after 3 weeks. CONCLUSIONS: A single dose of plant stanol esters does not change postprandial lipid and lipoprotein profiles. However, postprandial glucose responses may predict the effects of chronic plant stanol ester consumption.


Subject(s)
Diet , Lipid Metabolism/drug effects , Lipids/blood , Postprandial Period , Sitosterols/administration & dosage , Adult , Blood Glucose/analysis , Cross-Over Studies , Double-Blind Method , Female , Food, Fortified , Humans , Lipoproteins/blood , Male , Margarine , Young Adult
9.
Atherosclerosis ; 225(2): 521-33, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23083678

ABSTRACT

Abundant evidence over past decades shows that foods with added plant sterols and plant stanols lower serum LDL cholesterol concentrations. However, despite the overwhelming data, numerous scientific questions still remain. The objective of this paper is to summarize the considerations of 60 academic and industrial experts who participated in the scientific meeting in Maastricht, the Netherlands, on issues related to the health effects of plant sterols and plant stanols. The meeting participants discussed issues including efficacy profiling, heterogeneity in responsiveness, effects beyond LDL-C lowering, and food formulation aspects of plant sterol and stanol consumption. Furthermore, aspects related to the potential atherogenicity of elevated circulatory plant sterol concentrations were discussed. Until the potential atherogenicity of plant sterols is resolved, based on the results >200 clinical trials, the risk to benefit of plant sterol use is favorable. Evidence on these topics in plant sterol and plant stanol research was presented and used to reach consensus where possible. It was concluded that endpoint studies looking at plant sterol and plant stanol efficacy are needed, however, there was no clear opinion on the best marker and best design for such a study. Based on the current scientific evidence, plant sterols and plant stanols are recommended for use as dietary options to lower serum cholesterol.


Subject(s)
Anticholesteremic Agents/therapeutic use , Dietary Supplements , Hypercholesterolemia/drug therapy , Phytosterols/therapeutic use , Sitosterols/therapeutic use , Animals , Anticholesteremic Agents/adverse effects , Anticholesteremic Agents/chemistry , Anticholesteremic Agents/metabolism , Atherosclerosis/etiology , Biomarkers/blood , Chemistry, Pharmaceutical , Cholesterol/blood , Diet/adverse effects , Dietary Supplements/adverse effects , Humans , Hypercholesterolemia/blood , Nutrition Policy , Phytosterols/adverse effects , Phytosterols/chemistry , Phytosterols/metabolism , Risk Assessment , Risk Factors , Sitosterols/adverse effects , Sitosterols/chemistry , Sitosterols/metabolism , Treatment Outcome , Triglycerides/blood
10.
Eur J Clin Nutr ; 64(7): 720-6, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20197785

ABSTRACT

INTRODUCTION: Mushrooms are known for their immune modulating effect for which the polysaccharide fraction, mainly glucans, seem to be responsible. Fungal beta-glucans have been studied extensively, whereas little is known about mushroom alpha-glucans. We have earlier shown that the polysaccharide fraction from the mushroom A. bisporus, consisting 90% of alpha-glucans, induced in vitro tumor necrosis factor (TNF)alpha and nitric oxide production. The purpose of this study was to evaluate the effects of consuming. METHOD: A. bisporus alpha-glucan on ex vivo cytokine production by human peripheral mononuclear blood cells (PBMCs). A double-blind randomized trial was designed in which 56 mildly hypercholesterolemic subjects consumed a control fruit juice with no added alpha-glucans (200 ml/day) for a 2-week run-in period. For the next 5 weeks, the control group (N=30) continued consumption of the control fruit juice, whereas the intervention group (N=26) consumed the same fruit juice enriched with alpha-glucans from A. bisporus (5 g glucans/day). Changes in interleukin (IL)-1beta, IL-6 and TNFalpha cytokine production by lipopolysaccharide (LPS)-stimulated PBMCs were evaluated, as well as changes in T-helper (Th)1/Th2 cytokines by phytohemaggutinin (PHA)-stimulated PBMCs. RESULTS: Consumption of A. bisporus alpha-glucans lower LPS-induced TNFalpha production by 69% (P=0.017) as compared with the control group, whereas no effect on IL-1beta and IL-6 was observed. No obvious Th1-Th2 skewing by PHA-stimulated PBMCs was observed. However, we observed a trend towards a decreased production of IL-12 and IL-10. CONCLUSION: Our current finding suggests that in vivo, alpha-glucans have lost their efficacy to stimulate the immune response as observed in our in vitro mouse model.


Subject(s)
Agaricus/chemistry , Biological Products/pharmacology , Cytokines/metabolism , Glucans/pharmacology , Immunologic Factors/pharmacology , Leukocytes, Mononuclear/drug effects , Tumor Necrosis Factor-alpha/metabolism , Aged , Female , Humans , Hypercholesterolemia , Leukocytes, Mononuclear/metabolism , Lipopolysaccharides , Male , Middle Aged , Phytohemagglutinins , Th1 Cells , Th2 Cells
11.
Eur J Clin Nutr ; 62(2): 263-73, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17487211

ABSTRACT

OBJECTIVE: The present study was designed to examine for the first time, side-by-side, the effects of plant sterol and stanol consumption on lipid metabolism and markers of antioxidant status, oxidative stress, endothelial dysfunction and low-grade inflammation in subjects on stable statin-treatment. DESIGN: Double-blind, randomized, placebo-controlled, intervention trial. SETTING: University. SUBJECTS: Forty-five patients on current statin treatment were recruited via newspaper advertisements. Data of 41 patients were used in statistical analysis. INTERVENTION: Subjects consumed margarine with no added plant sterols or stanols for 4 weeks and were then divided into three groups of 15 subjects. For the next 16 weeks, one group continued with the control margarine and the other two groups with either a plant sterol- or stanol (2.5 g/day)-enriched margarine. Blood was sampled at the end of the run-in and intervention periods. RESULTS: Plant sterol and stanol consumption significantly (P=0.026) reduced low-density lipoprotein (LDL) cholesterol by 0.34 mmol/l (95% confidence interval (CI), -0.67 to -0.04 mmol/l). No effects were shown on enzymatic and non-enzymatic antioxidants and markers of oxidative modification of lipids and DNA. In addition, no effect was found on soluble adhesion molecules, C-reactive protein and monocyte chemotactic protein-1 concentrations. CONCLUSIONS: We conclude that 16 weeks of plant sterol or stanol consumption did not affect markers of antioxidant status, oxidative stress, endothelial dysfunction and low-grade inflammation in patients on stable statin treatment, despite a significant reduction of LDL cholesterol.


Subject(s)
Endothelium, Vascular/drug effects , Lipid Metabolism/drug effects , Oxidative Stress/drug effects , Phytosterols/pharmacology , Sitosterols/pharmacology , Adolescent , Adult , Aged , Anticholesteremic Agents/pharmacology , Antioxidants/metabolism , C-Reactive Protein/drug effects , C-Reactive Protein/metabolism , Cholesterol, LDL/blood , Double-Blind Method , Female , Food, Fortified , Humans , Male , Margarine , Middle Aged , Oxidation-Reduction
12.
Int J Clin Pharmacol Ther ; 45(7): 377-84, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17725244

ABSTRACT

OBJECTIVE: Epidemiological studies have convincingly demonstrated a positive association between LDL-cholesterol (LDL-C) and coronary artery disease but, in the case of HDL-C, there is an inverse association. Administration of high doses of the antifungal agent ketoconazole (800 mg/d) reduces serum concentrations of total cholesterol and LDL-C and there is a tendency for an increase in HDL-C. Our goal was to examine whether high-dose itraconazole raises HDL-C in subjects with normal levels of cholesterol. PATIENTS AND METHODS: 8 male patients with onychomycosis received 2 one-week cycles of treatment with itraconazole at a dose of 400 mg once daily in an open, prospective exploratory trial. Serum levels of itraconazole and its active metabolite hydroxyitraconazole were determined using high-performance liquid chromatography at the end of each treatment cycle. Fasting levels of serum lipoproteins and triglycerides were measured twice using routine enzymatic assays at the beginning and end of each cycle. The effects of itraconazole and hydroxyitraconazole on HDL-C metabolism were assessed in vitro using a human Caco-2 cell line and analyzing apoA-I levels with an enzyme-linked immunosorbent assay. RESULTS: During itraconazole treatment total cholesterol and LDL-C decreased on average by 12% (p < 0.001) and 17% (p < 0.001), respectively, whereas HDL-C increased by 21% (p < 0.001). The ratio LDL: HDL-C, an index of atherogenic risk, decreased by 30% (p < 0.001). Incubation of Caco-2 cells in the presence of itraconazole and hydroxyitraconazole for 3 hours resulted in a significant increase in apoA-I concentration in the medium (913 and 412%, respectively) compared with control. CONCLUSION: In addition to its inhibitory effect on cholesterol synthesis, high-dose itraconazole (400 mg/d) causes a significant decrease in serum LDL-C and, in contrast to ketoconazole, a significant increase in HDL-C. In vitro studies with Caco-2 cells indicate that the latter observation might be caused by an increase in apoA-I levels.


Subject(s)
Antifungal Agents/therapeutic use , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Hand Dermatoses/blood , Itraconazole/therapeutic use , Onychomycosis/blood , Antifungal Agents/blood , Antifungal Agents/pharmacokinetics , Apolipoprotein A-I/metabolism , Caco-2 Cells , Cholesterol/blood , Hand Dermatoses/drug therapy , Humans , Itraconazole/analogs & derivatives , Itraconazole/blood , Itraconazole/pharmacokinetics , Male , Middle Aged , Onychomycosis/drug therapy , Triglycerides/blood
13.
Eur J Clin Nutr ; 60(8): 985-90, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16482072

ABSTRACT

OBJECTIVE: To assess the effects of plant sterol or stanol ester consumption on their incorporation into erythrocytes and their effects on osmotic fragility of red blood cells. DESIGN: Double-blind, randomized, placebo-controlled intervention trial. SUBJECTS AND INTERVENTION: Forty-one subjects on stable statin treatment - who already have increased serum plant sterol and stanol concentrations - first received for 4 weeks a control margarine. For the next 16 weeks, subjects were randomly assigned to one of three possible interventions. Eleven subjects continued with control margarine, 15 subjects with plant sterol ester enriched and 15 subjects with plant stanol ester-enriched margarine. Daily plant sterol or stanol intake was 2.5 g. Erythrocyte haemolysis was measured spectrophotometrically at five different saline concentrations. RESULTS: Despite significant (P = 0.004) increases of, respectively, 42 and 59% in cholesterol-standardized serum sitosterol and campesterol concentrations in the plant sterol group as compared to the control group, campesterol levels in the red blood cells did not change (P = 0.196). Osmotic fragility did not change significantly (P = 0.757) in the plant sterol and plant stanol groups as compared to the control group. CONCLUSION: We conclude that plant sterol and stanol ester consumption for 16 weeks does not change osmotic fragility of erythrocytes in statin-treated patients. SPONSORSHIP: Netherlands Organisation for Health Research and Development (Program Nutrition: Health, Safety and Sustainability, Grant 014-12-010).


Subject(s)
Anticholesteremic Agents/pharmacology , Erythrocytes/drug effects , Hypercholesterolemia/blood , Margarine , Phytosterols/pharmacology , Anticholesteremic Agents/therapeutic use , Cholesterol/analogs & derivatives , Cholesterol/blood , Double-Blind Method , Erythrocytes/metabolism , Esters , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypercholesterolemia/diet therapy , Hypercholesterolemia/drug therapy , Male , Middle Aged , Osmolar Concentration , Phytosterols/blood , Phytosterols/therapeutic use , Sitosterols/blood
14.
Eur J Clin Invest ; 34(11): 766-73, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15530150

ABSTRACT

BACKGROUND: In obese subjects, chronic low-grade inflammation contributes to an increased risk of metabolic abnormalities, which are reversed by weight loss. Sustained weight loss, however, is difficult to achieve and more insight into dietary approaches on anti-inflammatory responses in obese subjects is needed. In this respect, fish oil deserves attention. MATERIAL AND METHODS: Eleven obese men (BMI: 30-35 kg m(-2)) received daily fish oil (1.35 g n-3 fatty acids) or placebo capsules in random order for 6 weeks. Eight subjects continued with a weight reduction study that lasted 8 weeks. Mean weight loss was 9.4 kg. At the end of each experimental period a postprandial study was performed. RESULTS: Relative to fasting concentrations, interleukin-6 (IL-6) levels increased by 75% 2 h and by 118% 4 h after the meal (P < 0.001), when subjects consumed the control capsules. In contrast, C-reactive protein (C-RP) concentrations decreased slightly by 0.7% and 6.6% (P = 0.046), and those of plasminogen activator inhibitor-1 (PAI-1) antigen by, respectively, 26% and 53% (P < 0.001). Tumour necrosis factor-alpha (TNF-alpha; P = 0.330) and soluble TNF-receptor concentrations (sTNF-R55 and sTNF-R75; P = 0.451 and P = 0.108, respectively) did not change. Changes relative to fasting concentrations were not significantly affected by either fish oil or weight reduction. Absolute IL-6, C-RP, sTNF-R55, sTNF-R75, and PAI-1 antigen concentrations, however, were consistently lower after weight reduction, but not after fish oil consumption. CONCLUSION: For slightly obese subjects a moderate intake of fish oil does not have the same favourable effects on markers for a low-grade inflammatory state as weight reduction.


Subject(s)
Biomarkers/blood , Fish Oils/administration & dosage , Obesity/immunology , Plasminogen Activator Inhibitor 1/blood , Weight Loss/immunology , C-Reactive Protein/analysis , Capsules , Cross-Over Studies , Dietary Supplements , Docosahexaenoic Acids/administration & dosage , Docosahexaenoic Acids/blood , Double-Blind Method , Eicosapentaenoic Acid/administration & dosage , Eicosapentaenoic Acid/blood , Fasting , Humans , Interleukin-6/blood , Male , Obesity/blood , Postprandial Period , Receptors, Tumor Necrosis Factor/blood , Tumor Necrosis Factor-alpha/analysis
15.
Eur J Clin Invest ; 32(4): 242-50, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11952809

ABSTRACT

BACKGROUND: Differences in genetic constitution may affect cholesterol metabolism and responses to diet. Identification of common variations in genes related to dietary responsiveness is therefore an attractive goal to be able to prescribe individually tailored diets for the treatment of dyslipidaemia. MATERIALS AND METHODS: We have examined relationships between serum lipids and lipoproteins, cholesterol-standardized campesterol and lathosterol concentrations with genetic variation, and the presence of a gene-diet interaction between plant stanol ester consumption. Candidate genes were apolipoprotein A-IV (apoA-IV), scavenger receptor-BI (SR-BI), cholesterol ester transfer protein (CETP), 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and apolipoprotein E (apoE). These relations were examined in 112 nonhypercholesterolaemic subjects, of whom 70 consumed 3.8-4.0 g plant stanol esters a day for 8 weeks. RESULTS: At baseline, high-density lipoprotein (HDL) concentrations of 1.56 +/- 0.36 mmol L(-1) in SR-BI-2 allele carriers tended to be lower compared to the 1.72 +/- 0.42 mmol L(-1) in SR-BI-1/1 subjects (P = 0.069). Cholesterol standardized lathosterol concentrations were also lower in the SR-BI-2 allele carriers (P = 0.002). Furthermore, low-density lipoprotein (LDL) cholesterol concentrations in apoE2 subjects, were lower compared to the LDL cholesterol concentration in apoE3 group (P = 0.002) and apoE4 subjects (P < 0.001). No significant differences between the polymorphisms and dietary responsiveness to plant stanol ester consumption could be found, which indicates that it is unlikely that one of the single polymorphisms analysed in this study is a major factor in explaining the variation in serum LDL cholesterol responses. CONCLUSION: These findings suggest that all subjects who want to lower their cholesterol concentration, will benefit from plant stanol ester consumption, irrespective of their apoA-IV, SR-BI, HMG-CoA reductase, CETP, or apoE genotype.


Subject(s)
Apolipoproteins A/genetics , Apolipoproteins E/genetics , Carrier Proteins/genetics , Cholesterol/analogs & derivatives , Cholesterol/metabolism , Genetic Variation , Glycoproteins , Hydroxymethylglutaryl CoA Reductases/genetics , Membrane Proteins , Phytosterols , Receptors, Immunologic/genetics , Receptors, Lipoprotein , Sitosterols/pharmacology , Adult , CD36 Antigens , Cholesterol/blood , Cholesterol Ester Transfer Proteins , Cholesterol, LDL/blood , Diet , Female , Humans , Lipids/blood , Lipoproteins/blood , Lipoproteins, HDL/blood , Lipoproteins, LDL/blood , Male , Polymorphism, Genetic , Receptors, Scavenger , Scavenger Receptors, Class B
16.
J Lipid Res ; 42(12): 2030-8, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11734576

ABSTRACT

Some oxidized forms of cholesterol (oxysterols) are thought to be atherogenic and cytotoxic. Because plant sterols are structurally related to cholesterol, we examined whether oxidized plant sterols (oxyphytosterols) could be identified in human serum and soy-based lipid emulsions. We first prepared both deuterated and nondeuterated reference compounds. We then analyzed by gas-liquid chromatography-mass spectrometry the oxyphytosterol concentrations in serum from patients with phytosterolemia or cerebrotendinous xanthomatosis, in a pool serum and in two lipid emulsions. 7-Ketositosterol, 7 beta-hydroxysitosterol, 5 alpha, 6 alpha-epoxysitosterol, 3 beta,5 alpha,6 beta-sitostanetriol, and probably also 7 alpha-hydroxysitosterol were present in markedly elevated concentrations in serum from phytosterolemic patients only. Also, campesterol oxidation products such as 7 alpha-hydroxycampesterol and 7 beta-hydroxycampesterol were found. Interestingly, sitosterol was oxidized for approximately 1.4% in phytosterolemic serum, which is rather high compared with the approximate 0.01% oxidatively modified cholesterol normally seen in human serum. The same oxyphytosterols were also found in two lipid emulsions in which the ratio of oxidized sitosterol to sitosterol varied between 0.038 and 0.041. In conclusion, we have shown that oxidized forms of plant sterols are present in serum from phytosterolemic patients and two frequently used soy-based lipid emulsions. Currently, it is unknown whether oxyphytosterols affect health, as has been suggested for oxysterols. However, 7 beta-hydroxycholesterol may be one of the more harmful oxysterols, and both sitosterol and campesterol were oxidized into 7 beta-hydroxysitosterol and 7 beta-hydroxycampesterol. The relevance of these findings therefore deserves further exploration.


Subject(s)
Gas Chromatography-Mass Spectrometry/methods , Lipids/blood , Phytosterols/blood , Phytosterols/metabolism , Child , Cholesterol/analogs & derivatives , Cholesterol/analysis , Female , Humans , Oxidation-Reduction , Phytosterols/chemistry
17.
Atherosclerosis ; 157(2): 375-81, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11472737

ABSTRACT

The hypolipidemic and anti-atherosclerotic effects of vegetable oil- and wood-based dietary plant stanol esters were compared in female apoE*3-Leiden transgenic mice at relevant plasma cholesterol levels. The plant stanol esters derived from vegetable oil (sitostanol 65.7%, campestanol 30.1%) had different contents of sitostanol and campestanol than the plant stanol esters derived from wood (sitostanol 87.6%, campestanol 9.5%) or from a mixture of vegetable oil and wood (sitostanol 73.0%, campestanol 24.7%). The mice (10 per group) received for 38 weeks a control diet or diets containing 1.0% (w/w) plant stanol esters derived from either vegetable oil, wood or a mixture of both. Vegetable oil (-46%), wood (-42%) and vegetable oil/wood (-51%) plant stanol esters decreased the plasma cholesterol levels (P<0.0001) by reducing the cholesterol content in plasma very low density-, intermediate density- and to a lesser extent in low density-lipoprotein. Plant stanol ester feeding did not change plasma triglyceride levels. Dietary plant stanol esters reduced the atherosclerotic lesion area by 91+/-13% (vegetable oil), 97+/-4% (wood) and 78+/-34% (vegetable oil/wood) (P<0.0001) and the severity from regular intimal fatty streaks/mild plaques (on average type 2--3 lesions) in controls to individual intimal foam cells (

Subject(s)
Apolipoproteins E/genetics , Arteriosclerosis/genetics , Arteriosclerosis/pathology , Dietary Fats, Unsaturated/pharmacology , Mutation , Plant Oils/pharmacology , Sitosterols/pharmacology , Animals , Apolipoprotein E3 , Arteriosclerosis/blood , Cholesterol/blood , Female , Mice , Mice, Transgenic/genetics , Severity of Illness Index , Triglycerides/blood , Wood
18.
Nutr Metab Cardiovasc Dis ; 11(1): 31-40, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11383323

ABSTRACT

Functional foods enriched with plant sterols and stanols are on sale in many countries. Due to their structural similarity with cholesterol, these additives lower intestinal absorption of cholesterol, resulting in a 10-15% reduction in LDL-cholesterol when their daily intakes are 2-3 g. They are also effective as part of a cholesterol-lowering diet and in combination with cholesterol-lowering drugs. Estimates for the absorption of plant sterols (sitosterol and campesterol) and of campestanol are around 10%, and for sitostanol less than 5%. Lipid-standardized plasma levels are very low, but increase when statins are used. Extensive toxicological evaluation studies have not revealed any harmful side-effects. In human studies, side-effects were comparable to placebo treatment. However, lipid-standardized levels of the hydrocarbon carotenoids may decrease, without leaving the normal range. Together, these findings indicate that these functional foods have great potential in the prevention of coronary heart disease. However, post-marketing surveillance for example for functional foods in general is necessary to monitor possible adverse effects and describe consumers and consumption patterns.


Subject(s)
Anticholesteremic Agents/pharmacology , Cardiovascular Diseases/metabolism , Lipid Metabolism , Phytosterols/pharmacology , Anticholesteremic Agents/adverse effects , Anticholesteremic Agents/pharmacokinetics , Cardiovascular Diseases/prevention & control , Cholesterol/metabolism , Diet , Food, Organic , Humans , Intestinal Absorption , Phytosterols/adverse effects , Phytosterols/pharmacokinetics , Risk Factors , Safety , Sitosterols/adverse effects , Sitosterols/pharmacokinetics , Sitosterols/pharmacology
19.
Arterioscler Thromb Vasc Biol ; 21(6): 1046-52, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11397718

ABSTRACT

Dietary plant stanols lower serum cholesterol levels in humans and in hyperlipidemic rodents, mainly by inhibition of the intestinal cholesterol absorption. We used female apolipoprotein E*3-Leiden transgenic mice to investigate the consequences of this effect on serum lipid levels and hepatic lipid metabolism. Five groups of 6 or 7 mice received for 9 weeks a diet containing 0.25% cholesterol and 0.0%, 0.25%, 0.5%, 0.75%, or 1.0% (wt/wt) plant stanols (sitostanol 88% [wt/wt], campestanol 10% [wt/wt]) esterified to fatty acids. Compared with the control diet, plant stanol ester treatment dose-dependently reduced serum cholesterol levels by 10% to 33% (P<0.05), mainly in very low density lipoproteins (VLDLs), intermediate density lipoproteins, and low density lipoproteins. Furthermore, 1.0% of the dietary plant stanols significantly decreased the liver contents of cholesteryl esters (-62%), free cholesterol (-31%), and triglycerides (-38%) but did not change the hepatic VLDL-triglyceride and VLDL-apolipoprotein B production rates. However, plant stanol ester feeding significantly decreased the amounts of cholesteryl esters and free cholesterol incorporated in nascent VLDLs by 72% and 30%, respectively, resulting in a net 2-fold decreased VLDL cholesterol output. Liver mRNA levels of low density lipoprotein receptors, 3-hydroxy-3-methylglutaryl coenzyme A synthase, cholesterol 7alpha-hydroxylase, and sterol 27-hydroxylase were not changed by plant stanol ester feeding. Nevertheless, the serum lathosterol-to-cholesterol ratio was significantly increased by 23%, indicating that dietary plant stanol esters increased whole-body cholesterol synthesis. Plant stanol esters also significantly decreased the cholesterol saturation index in bile by 55%. In conclusion, in apolipoprotein E*3-Leiden transgenic mice, plant stanol ester feeding dose-dependently lowered serum cholesterol levels as a result of a reduced secretion of VLDL cholesterol. This was caused by a decreased hepatic cholesterol content that also resulted in a lowered biliary cholesterol output, indicative of a reduced lithogenicity of bile in these mice.


Subject(s)
Apolipoproteins E/genetics , Bile/metabolism , Cholesterol, VLDL/metabolism , Hypolipidemic Agents/pharmacology , Sitosterols/pharmacology , Animals , Apolipoprotein E3 , Cholesterol/blood , Cholesterol, VLDL/blood , Diet , Female , Hypolipidemic Agents/blood , Lipoproteins/blood , Lipoproteins, VLDL/chemistry , Lipoproteins, VLDL/metabolism , Liver/metabolism , Mice , Mice, Inbred C57BL , Mice, Transgenic , Sitosterols/blood
20.
Metabolism ; 50(5): 520-9, 2001 May.
Article in English | MEDLINE | ID: mdl-11319712

ABSTRACT

Plant stanols lower intestinal cholesterol absorption. This causes a decrease in serum low-density lipoprotein (LDL)-cholesterol, despite a compensatory increase in cholesterol synthesis. We therefore hypothesized that plant stanols also change LDL-cholesterol-standardized concentrations of ubiquinol-10 (a side product of the cholesterol synthesis cascade) and of those fat-soluble antioxidants that are mainly carried by LDL. To examine this, 112 nonhypercholesterolemic subjects consumed low erucic acid rapeseed oil (LEAR)-based margarine and shortening for 4 weeks. For the next 8 weeks, 42 subjects consumed the same products, while the other subjects received products with vegetable oil-based stanols (2.6 g sitostanol plus 1.2 g campestanol daily, n = 36) or wood-based stanols (3.7 g sitostanol plus 0.3 g campestanol daily, n = 34). Consumption of both plant stanol ester mixtures increased cholesterol synthesis and lowered cholesterol absorption, as indicated by increased serum cholesterol-standardized lathosterol and decreased plant sterol concentrations, respectively. Compared with the control group, absolute plasma ubiquinol-10 concentrations were lowered by 12.3% +/- 18.9% (-0.14 microg/mL v. the control group; P =.004; 95% confidence interval [CI] for the difference in changes, -0.05 to -0.22 microg/mL) in the vegetable oil-based group and by 15.4% +/- 13.0% (-0.17 microg/mL v. the control group; P <.001; 95% CI for the difference, -0.08 to -0.27 microg/mL) in the wood-based group. Changes in LDL-cholesterol-standardized ubiquinol-10 concentrations were not significantly changed. The most lipophylic antioxidants, the hydrocarbon carotenoids (beta-carotene, alpha-carotene, and lycopene), decreased most, followed by the less lipophylic oxygenated carotenoids (lutein/zeaxanthin and beta-cryptoxanthin) and the tocopherols. These reductions were related to the reduction in LDL, which carry most of these antioxidants. The decrease in the hydrocarbon carotenoids, however, was also significantly associated with a decrease in cholesterol absorption. LDL-cholesterol-standardized antioxidant concentrations were not changed, except for beta-carotene, which was still, although not significantly, lowered by about 10%. We conclude that the increase in endogenous cholesterol synthesis during plant stanol ester consumption does not result in increased LDL-cholesterol-standardized concentrations of ubiquinol-10, a side product of the cholesterol synthesis cascade. Furthermore, decreases in absolute fat-soluble antioxidant concentrations are related to decreases in LDL-cholesterol. However, for the most lipophylic carotenoids, some of the reduction was also related to the decrease in cholesterol absorption.


Subject(s)
Antioxidants/analysis , Diet , Phytosterols/administration & dosage , Plants, Edible/chemistry , Sitosterols/administration & dosage , Ubiquinone/analogs & derivatives , Ubiquinone/blood , Absorption , Adolescent , Adult , Carotenoids/blood , Cholesterol/biosynthesis , Cholesterol/blood , Cholesterol/metabolism , Cholesterol, LDL/blood , Erucic Acids/administration & dosage , Fats , Fatty Acids, Monounsaturated , Female , Humans , Male , Margarine , Middle Aged , Plant Oils/administration & dosage , Rapeseed Oil , Solubility , Vitamin A/blood , Vitamin E/blood , Wood
SELECTION OF CITATIONS
SEARCH DETAIL
...